Dilacor (Diltiazem) is a medication used in cardiovascular therapeutic contexts, applied across domains where additional symptomatic support is needed to address several conditions characterized by heightened physiological activity in the heart and blood vessels.

---

Key Therapeutic Uses and Patient Benefits

This medication is commonly used to help manage symptoms related to symptom domains including high blood pressure (hypertension), angina (chest pain), and certain atrial arrhythmias like atrial fibrillation and flutter.

In situations where patients experience these conditions, Dilacor plays a role in managing symptoms that interfere with daily comfort. For example, it contributes to easing the overall symptom load of chest discomfort and supports increased exercise tolerance.

In managing heart rhythm issues, the medication may assist with supporting a slower, more controlled heart rate. This assists with maintaining functional stability when symptoms create noticeable physiological strain. It is applied across clinical settings that involve acute or unstable symptom patterns, and in the case of hypertension, it may assist with reducing long-term risk associated with uncontrolled high blood pressure.

“The medication is commonly used across conditions presenting with acute episodes and in situations involving recurrent or episodic manifestations.”

Quick Fact: Applied in therapeutic contexts for Anginal Pain and Rapid Heartbeat.

Regulatory References

1. NIH StatPearls clinical overview

Who Can and Cannot Use Dilacor?

Official regulatory documents define strict criteria for the eligibility and non-eligibility of patients for Dilacor (Diltiazem hydrochloride).

Absolute Contraindications

Use of the medicine is absolutely prohibited in the following populations:

• Patients with Sick Sinus Syndrome or Second-/Third-Degree Atrioventricular Block, unless a functioning ventricular pacemaker is present.
• Patients with Severe Hypotension (Systolic Blood Pressure below 90 mm Hg), Cardiogenic Shock, or Acute Myocardial Infarction combined with Pulmonary Congestion.
• Patients with Atrial Fibrillation or Flutter associated with an accessory bypass tract (e.g., Wolff-Parkinson-White Syndrome).
• Individuals with a documented hypersensitivity to diltiazem hydrochloride.

Restricted and Conditional Use

Certain patient groups require caution or are restricted due to limited data:

• Organ Function: Use must be with caution in patients with impaired hepatic (liver) or renal (kidney) function and in those with impaired ventricular function/heart failure.
• Pediatric Status: Safety and efficacy have not been established in the pediatric population; therefore, use is not recommended.
• Pregnancy/Lactation: Use during pregnancy is restricted, recommended only if the potential benefit justifies the potential risk. An alternative method of infant feeding may be necessary during lactation due to drug excretion in human milk.

Interactions with other medicines and products

Dilacor (Diltiazem) is associated with officially documented interaction patterns primarily through pharmacokinetic and pharmacodynamic mechanisms, as stated in regulatory labeling.

Contraindicated Combinations

The co-administration of Dilacor is strictly contraindicated with certain agents due to severe adverse outcomes. These combinations include intravenous beta-blockers, Ivabradine, Lomitapide, and Dantrolene (infusion). These prohibitions are based on the risk of excessive heart rate slowing, conduction disturbances, or significantly altered drug exposure.

---

Pharmacokinetic Interactions

Dilacor is an inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme and a P-glycoprotein (P-gp) inhibitor. This inhibition leads to an increased plasma concentration of numerous co-administered drugs that are metabolized by these pathways, including Simvastatin, Triazolam, Buspirone, and Cyclosporine. Conversely, co-administration with CYP3A4 inducers such as Cimetidine can increase Diltiazem levels, while CYP3A4 inducers like Rifampicin may decrease Diltiazem’s exposure.

---

Pharmacodynamic Effects and Substance Interactions

Additive effects on cardiac conduction can occur with other agents that slow the heart rate, such as oral beta-blockers and Digoxin, and co-administration with general anesthetics may potentiate vascular dilation. The consumption of Grapefruit Juice may increase Diltiazem's exposure, and a high-fat meal may slightly alter the absorption rate of extended-release formulations. The potential for drug accumulation is also noted in populations with hepatic impairment.

Calcium Channel Blockade and Use-Dependence

The fundamental molecular interaction of Diltiazem is the blockade of the L-type Voltage-Gated Calcium Channels (L- VGCCs). Diltiazem’s affinity for these channels is use-dependent, meaning it preferentially blocks them when the cardiac tissues are rapidly depolarizing. This molecular action reduces the influx of extracellular Ca^2+ required for cellular excitation and contraction, which precedes all downstream physiological consequences.

Dual Action on Cardiac Conduction and Myocardial Force

Diltiazem’s mechanism affects the heart's function across two primary domains. In the cardiac conduction system (SA and AV nodes), reduced Ca^2+ current leads to negative chronotropy (slowing the heart rate) and negative dromotropy (delaying electrical signal transmission). Simultaneously, in the myocardium (heart muscle), decreased Ca^2+ availability translates to a negative inotropic effect, reducing the force of contraction.

Vasodilation and Reduced Cardiac Workload

The final mechanistic domain involves the relaxation of arterial smooth muscle, where Ca^2+ blockade causes vasodilation and decreases resistance. By combining reduced heart rate, weaker contraction, and lower vascular resistance, the overall mechanism of Diltiazem produces a decrease in the mechanical workload and oxygen demand of the heart.

How to Use Dilacor: Official Administration Guidelines

Dilacor, containing Diltiazem hydrochloride, is administered through two primary routes based on the clinical scenario: oral for long-term chronic management and intravenous (IV) for acute medical settings.

---

Oral Dosing and Scheduling

Oral administration involves both immediate-release tablets and extended-release capsules or tablets. The extended-release forms are typically taken once daily at strengths ranging from an initial dose of 180 mg up to a maximum of 540 mg daily, depending on the specific formulation. Dose adjustments are typically made at intervals of 7 to 14 days to allow for observed patient response. Immediate-release forms are generally taken multiple times per day (e.g., three to four times daily), with common starting doses of 30 mg.

Administration Requirements

For proper use, extended-release capsules or tablets must be swallowed whole and should not be crushed, chewed, or divided. This requirement ensures the medicine's controlled release mechanism is maintained throughout the dosing interval. Immediate-release tablets are often taken before meals and at bedtime.

---

Acute Intravenous Use

Intravenous diltiazem is used in acute hospital settings and requires continuous ECG monitoring. The administration begins with an initial bolus of 0.25 mg/kg given over 2 minutes. If needed, a second bolus of 0.35 mg/kg can be administered 15 minutes later, followed by a continuous infusion that is usually limited to a maximum duration of 24 hours.

Population-Specific Adjustments

Official guidance states that a lower starting dose and slower titration are necessary for older adults and patients with impaired hepatic or renal function. Use in pediatric patients has not been established and is generally not recommended.

Research evidence / Overview of studies for Dilacor

The research base for Dilacor (diltiazem) is defined by official clinical trials and regulatory reviews that examined its use for several cardiovascular conditions. This overview describes the structure of that evidence, focusing only on the types of studies conducted, what they monitored, and the acknowledged research limitations. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

---

Evidence Overview for High Blood Pressure (Hypertension)

Research examining the use of Dilacor for conditions where blood pressure is elevated was studied by researchers who explored systemic and functional imbalance. These studies included short-term Randomized Controlled Trials (RCTs). Researchers primarily monitored outcomes related to systemic imbalance, specifically measuring reductions in systolic and diastolic blood pressure. Long-term evidence derived from systematic reviews and aggregated data also explores the association between these blood pressure measurements and serious outcomes like stroke or heart attack. The follow-up durations were limited in many initial trials, and data for certain groups remain insufficient.

---

Evidence Overview for Chronic Stable Angina Pectoris (Chest Pain)

Dilacor was evaluated in studies for conditions involving periods of heightened symptoms, specifically chronic stable angina pectoris. The core evidence comes from short-to-intermediate-term placebo-controlled trials. Researchers focused on outcomes related to physical discomfort and daily functioning. Studies monitored measurements of change in Exercise Tolerance Time (ETT) and the reported number of anginal attacks. The follow-up durations were limited in many functional trials, and the data primarily address symptomatic relief and functional capacity.

---

Areas of Research Uncertainty and Study Limitations

For high blood pressure, long-term effects are not characterized by single, decade-long RCTs focusing only on Dilacor; instead, long-term data often stems from large systematic reviews combining different medication classes. For arrhythmias, the comparative evidence is limited against some currently used treatments, and evidence quality varies across studies, particularly in the acute care settings. Overall, specific long-term, hard-outcome data remain areas where more research is ongoing to provide greater certainty. Dedicated studies focusing exclusively on special populations, such as young children, are typically insufficient.

Key Studies & References

1. Diltiazem - StatPearls - NCBI Bookshelf (NIH)
2. National List of Essential Medicines – 2022 (India - Diltiazem listed for Angina)

Common questions about Dilacor (FAQ)

Q: What is Dilacor used for?

According to regulatory documents, the primary uses for Dilacor are the treatment of high blood pressure (hypertension) and the control of angina (chest pain). It is also sometimes prescribed to manage certain types of abnormal heart rhythms.

Q: Is Dilacor a blood pressure medicine?

Official regulatory documents state that the active ingredient in Dilacor, diltiazem, is prescribed for the treatment of hypertension, which is commonly known as high blood pressure. The drug works to help control and maintain healthy blood pressure levels.

Q: Is it true that Dilacor helps with chest pain (angina)?

Yes, official documents and regulatory information state that diltiazem, the drug in Dilacor, is approved for the treatment and control of angina, which is a type of chest pain.

Q: Why is Dilacor sometimes prescribed for atrial fibrillation?

The drug is noted in official sources for its use in managing certain abnormal heart rhythms, or arrhythmias. This includes helping to control the rate of the heartbeat in conditions like atrial fibrillation.

Q: How long does it take for Dilacor to start working?

Regulatory guidelines advise that the dose is typically adjusted over intervals of 7 to 14 days. This timeframe is used to assess the patient's full response, indicating that the full therapeutic effect develops over a period of time.

Q: How quickly will Dilacor lower blood pressure?

While some blood pressure lowering begins relatively quickly, official guidance for dose adjustment is based on observing the full therapeutic effect. Therefore, the optimal level of blood pressure control is usually established after a period of 7 to 14 days of treatment at a stable dose.

Q: How long does the effect of Dilacor typically last?

The duration of the drug's effect depends on the specific form prescribed. Extended-release formulations are generally taken once daily to provide a sustained effect over the full day, while standard tablets are formulated to require administration more than once daily.

Q: What happens if a dose of Dilacor is missed?

Official guidance in patient information describes a general principle: if a dose is missed, it is often recommended to take it as soon as remembered, unless the next dose is due shortly. If that is the case, the instruction is to typically skip the missed dose and resume the normal schedule.

Q: Does Dilacor need to be taken at a specific time of day?

The extended-release form of the medicine is generally taken once a day. Official guidance suggests that for the best therapeutic results, the drug should consistently be administered around the same time each day.

Q: Is Dilacor a medication that is taken long-term?

According to official patient information, when the drug is prescribed for chronic conditions like high blood pressure or angina, it is generally intended for long-term use to manage the condition over time.

Q: Does Dilacor cure the underlying condition or just manage the symptoms?

Regulatory information explicitly states that Dilacor helps to control conditions like high blood pressure and angina. It is important to know that the medication manages symptoms and reduces risks but does not cure the underlying condition.

Q: What are the most commonly reported side effects of Dilacor?

Official product information lists common side effects, which may include headache, dizziness, and constipation. Swelling, particularly in the hands, ankles, or feet (edema), is also a frequently reported effect.

Q: Is it normal to feel tired after first starting Dilacor?

Official adverse event reports indicate that fatigue or unusual tiredness are sometimes reported as a side effect. This is listed as occurring in a small percentage of patients during clinical trials.

Q: Can Dilacor cause serious heart or rhythm problems?

Yes, the official label includes warnings about the potential for serious heart-related adverse effects. These include a very slow heart rate (bradycardia), very low blood pressure (hypotension), and effects on the heart's electrical system, such as changes in conduction.

Q: Does Dilacor affect the liver or kidneys?

Official regulatory information indicates the drug has the potential to cause liver damage and may alter blood test results related to liver function. Caution is advised for patients with existing impaired hepatic (liver) or renal (kidney) function because of how the body clears the medicine.

Q: Can Dilacor cause weight gain or fluid retention?

Fluid retention and swelling in the lower limbs, known as edema, are listed in official documents as commonly reported side effects of this medication.

Q: What should be done if a side effect of Dilacor is bothersome?

Regulatory patient information advises that if any side effects are severe, persistent, or become a concern, a healthcare professional may be consulted. This allows for an evaluation of the symptoms.

Q: Does Dilacor interact with other types of heart or blood pressure medicines?

Official product information notes that diltiazem may interact with other heart or blood pressure medicines. For example, when combined with drugs like beta-blockers or digoxin, there may be an additive effect on slowing the heart rate or conduction.

Q: Can alcohol be consumed while taking Dilacor?

Official sources describe the consumption of alcohol while taking this medication as warranting caution. Alcohol can potentially cause a further decrease in blood pressure, which may increase the risk of experiencing dizziness, lightheadedness, or fainting.

Q: Does Dilacor interact with over-the-counter pain relievers like ibuprofen?

Information sourced from regulatory documents suggests that common over-the-counter medications like NSAIDs (e.g., ibuprofen) may reduce the effectiveness of some blood pressure medicines. Paracetamol (acetaminophen) is often noted as an alternative option for pain relief in these contexts.

Q: What types of foods, if any, should be limited when taking Dilacor?

The most frequently noted interaction concerning food is with grapefruit juice. Official sources advise that consuming grapefruit juice may lead to an increase in the amount of the medication in the bloodstream.

Q: Can Dilacor be taken alongside daily vitamins or supplements?

Regulatory patient guidance advises caution with many supplements and herbal remedies. These products are often not formally tested for interactions with prescription medicines, and certain substances, such as St. John’s wort, may affect how the body processes the medication.

Q: Does Dilacor have specific contraindications for people with certain existing health conditions?

Yes, regulatory documents list specific conditions where Dilacor should generally not be used, known as contraindications. These conditions include very low blood pressure (hypotension) or certain serious heart conduction issues such as sick sinus syndrome (unless a pacemaker is in place).

Q: Is Dilacor considered safe for use during pregnancy?

The official stance is that use during pregnancy is generally not recommended. It is advised only if the potential benefit to the mother is considered to outweigh the potential risks to the developing fetus.

Q: Is Dilacor safe to use while breastfeeding?

Official information confirms that the active ingredient, diltiazem, is excreted into human milk. Therefore, official guidance often notes that the decision involves balancing whether to discontinue the drug or discontinue nursing due to the unknown effects on the nursing infant.

Q: Why do some people use Dilacor if they are already taking other pills for blood pressure?

Official prescribing information notes that Dilacor can be used alone or in combination with other medications. It is often added to an existing treatment regimen to enhance overall blood pressure control or to address specific therapeutic goals that the initial medication may not fully cover.

Q: Is Dilacor classified as a controlled substance?

According to official regulatory classifications, the active ingredient diltiazem is not classified as a controlled substance in the United States.

Q: Where can a patient find the official prescribing information for Dilacor?

The official, comprehensive prescribing information is publicly available on government-maintained websites. This information can be found on resources such as the US FDA’s DailyMed database or the NIH’s MedlinePlus Drug Information service.

The extended-release capsules of Dilacor (diltiazem hydrochloride) must be stored at 25°C (77°F), with acceptable temperature variations between 15° to 30°C (59° to 86°F), according to USP Controlled Room Temperature standards.

Storage Requirements

Storage Factor	Official Requirement
Temperature	25 C (77 F); avoid freezing or excess heat.
Protection	Avoid excessive humidity and direct light.
Container	Keep in the original container, tightly closed and away from moisture.
Child Safety	Keep out of the reach of children; the container should feature a child-resistant closure.

Disposal Instructions

Patients should ask a healthcare professional for guidance on the proper disposal of unused or expired medicine. Unneeded medication should not be kept, nor should it be flushed down the toilet or poured into a drain unless specific official instructions permit this action.